Previous 10 | Next 10 |
2024-06-05 11:52:26 ET Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's dis...
2024-06-03 17:24:06 ET Novartis AG (NVS) Investor Event at ASCO Conference Call June 02, 2024 07:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global...
2024-05-31 12:19:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports positive Phase 3 data for remibrutinib for chronic hives Novartis end...
2024-05-31 11:11:10 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis ending development of phas...
2024-05-30 11:54:09 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports Phase 3 results for IgA nephropathy treatment Novartis AG (NVS) Q1 20...
2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...
2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...
2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...
2024-05-28 10:20:20 ET Summary Asahi Kasei will acquire Calliditas Therapeutics AB (publ) for $1.1 billion, representing an 83% premium to the closing price on the Stockholm exchange and a 74% premium to the Nasdaq closing price. The primary asset of interest in the acquisition is...
2024-05-28 09:44:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results ADHD diagnoses increasing, becoming...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...